JP2023548046A5 - - Google Patents
Info
- Publication number
- JP2023548046A5 JP2023548046A5 JP2023524629A JP2023524629A JP2023548046A5 JP 2023548046 A5 JP2023548046 A5 JP 2023548046A5 JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023548046 A5 JP2023548046 A5 JP 2023548046A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- complement
- patient
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105018P | 2020-10-23 | 2020-10-23 | |
| US63/105,018 | 2020-10-23 | ||
| PCT/US2021/056153 WO2022087339A1 (en) | 2020-10-23 | 2021-10-22 | Methods of treating patients having complement disorders using anti-c5 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548046A JP2023548046A (ja) | 2023-11-15 |
| JP2023548046A5 true JP2023548046A5 (https=) | 2024-10-29 |
Family
ID=78695818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524629A Pending JP2023548046A (ja) | 2020-10-23 | 2021-10-22 | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240018220A1 (https=) |
| EP (1) | EP4232473A1 (https=) |
| JP (1) | JP2023548046A (https=) |
| CA (1) | CA3196434A1 (https=) |
| WO (1) | WO2022087339A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| KR102365871B1 (ko) * | 2017-01-31 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| CN118512588A (zh) * | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| CA3274059A1 (en) * | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
-
2021
- 2021-10-22 CA CA3196434A patent/CA3196434A1/en active Pending
- 2021-10-22 JP JP2023524629A patent/JP2023548046A/ja active Pending
- 2021-10-22 EP EP21810811.6A patent/EP4232473A1/en active Pending
- 2021-10-22 WO PCT/US2021/056153 patent/WO2022087339A1/en not_active Ceased
- 2021-10-22 US US18/032,959 patent/US20240018220A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7227312B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| TWI660972B (zh) | 抗ｍｃａｍ抗體及相關使用方法 | |
| JP6262715B2 (ja) | ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用 | |
| JP2023548046A5 (https=) | ||
| TW201934581A (zh) | 抗ｂ７－ｈ４抗體、其抗原結合片段及其醫藥用途 | |
| JP2018501813A5 (https=) | ||
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| TWI869542B (zh) | 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途 | |
| AU2011336702A1 (en) | Neoantibodies for diagnosing tissue injury | |
| TWI836070B (zh) | 抗trop-2抗體、其抗原結合片段及其醫藥用途 | |
| JP2023548046A (ja) | 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| TW202144433A (zh) | 抗體或其抗原結合片段、其製備方法及醫藥用途 | |
| EP4393949A1 (en) | Pharmaceutical composition containing fusion protein | |
| WO2024245388A1 (zh) | 抗pvrig抗体及其应用 | |
| HK40036076A (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| JP6143209B1 (ja) | 自己免疫疾患用または難治性血管炎用の治療剤、および、これらの疾患の診断のためのデータの取得方法 | |
| HK40036076B (en) | Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof | |
| TW202547857A (zh) | 抗ｈａｓ抗體及其組合物 | |
| HK40032645B (zh) | 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 |